In Vivo Services for Disease Modeling | Melior Discovery
In Vivo Services for Disease Modeling | Melior Discovery
In Vivo Services for Disease Modeling | Melior Discovery
Description: Melior Pharmaceuticals is a mid-stage biopharmaceuticals company in Pennsylvania that develops therapies for diabetes and parkinson’s disease.
biopharmaceutical company (32) biopharmaceutical research company (4) biopharmaceutical development company (4) melior pharmaceuticals pennsylvania (4) biopharma investments (4)
Melior Pharmaceuticals is a mid-stage biopharmaceutical company developing a pipeline of innovative, de-risked drug candidates in disease areas with significant unmet needs. Melior leverages its proprietary drug screening technology to identify new and patentable uses for drugs that have been developed for other indications and that have significant clinical safety history.
Our leading drug candidates are in early to mid-stage clinical development for Type 2 Diabetes, Nonalcoholic Steatohepatitis (NASH), Parkinson’s Disease and Sleep Disorders.
Melior’s pipeline includes, (1) Tolimidone, a novel lyn kinase activator, currently in development for Type 2 Diabetes and NASH, and (2) Mesocarb, a highly selective and well tolerated dopamine reuptake inhibitor, in development for Parkinson’s Disease and Sleep Disorders.
In Vivo Services for Disease Modeling | Melior Discovery
In Vivo Services for Disease Modeling | Melior Discovery
In Vivo Services for Disease Modeling | Melior Discovery